Skip to main content
Top
Published in: Breast Cancer Research 2/2005

01-06-2005 | Poster Presentation

Who gets cancer?

Authors: BA Nexø, U Vogel, K Overvad, O Raaschou-Nielsen, A Tjønneland

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

We have looked for genetic differences influencing cancer risk in the general human population. One human chromosomal region that recent data indicate as important for cancer risk is 19q13.2-3, more specifically a 69 kb region including the genes XPD, RAI, ASE1 and ERCC1. We and others have produced evidence of association between this region and occurrence of a variety of cancers, including basal cell carcinoma, melanoma, lung cancer, glioma, breast cancer, bladder cancer, and possibly head and neck cancer (see for instance [1]). A recent search along the region for markers with maximal association to basal cell carcinoma has led to a focus on the gene RAI [2]. Moreover, the effect appears to be strongest among fairly young persons (<56 years of age). …
Literature
1.
go back to reference Nexø BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, Thomsen BL, Wallin H, Overvad K, Tjønneland A: A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the genes RAI is indicative of postmenopausal breast cancer before age 55. Carcinogenesis. 2003, 24: 899-904. 10.1093/carcin/bgg043.CrossRefPubMed Nexø BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, Thomsen BL, Wallin H, Overvad K, Tjønneland A: A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the genes RAI is indicative of postmenopausal breast cancer before age 55. Carcinogenesis. 2003, 24: 899-904. 10.1093/carcin/bgg043.CrossRefPubMed
2.
go back to reference Rockenbauer E, Bendixen MH, Bukowy Z, Yin J, Jacobsen NR, Hedayati MA, Vogel U, Grossman L, Bolund L, Nexø BA: Association of chromosome 19q13.2-3 with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts. Carcinogenesis. 2002, 23: 1149-1153. 10.1093/carcin/23.7.1149.CrossRefPubMed Rockenbauer E, Bendixen MH, Bukowy Z, Yin J, Jacobsen NR, Hedayati MA, Vogel U, Grossman L, Bolund L, Nexø BA: Association of chromosome 19q13.2-3 with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts. Carcinogenesis. 2002, 23: 1149-1153. 10.1093/carcin/23.7.1149.CrossRefPubMed
3.
go back to reference Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, Louis DN: Transcript map of the 23.7 Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res. 2002, 62: 4100-4108.PubMed Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, Louis DN: Transcript map of the 23.7 Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res. 2002, 62: 4100-4108.PubMed
4.
go back to reference Slager SL, Schaid DJ, Cunningham JM, McDonnell SK, Marks AF, Peterson BJ, Hebbring SJ, Anderson S, French AJ, Thibodeau SN: Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet. 2003, 72: 759-762. 10.1086/368230.CrossRefPubMedPubMedCentral Slager SL, Schaid DJ, Cunningham JM, McDonnell SK, Marks AF, Peterson BJ, Hebbring SJ, Anderson S, French AJ, Thibodeau SN: Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet. 2003, 72: 759-762. 10.1086/368230.CrossRefPubMedPubMedCentral
Metadata
Title
Who gets cancer?
Authors
BA Nexø
U Vogel
K Overvad
O Raaschou-Nielsen
A Tjønneland
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1099

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue

Oral Presentation

Apoptotic chemotherapies

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine